Summarize This Guide with AI
The page title, key topics and source link are passed to your selected tool in a prepared prompt.
On this page
Fatigue, low desire or one low blood result does not by itself diagnose testosterone deficiency. Assessment brings compatible symptoms together with hormone measurements taken under appropriate conditions and confirmed when low. The cause and any plans for children matter before treatment is considered.
Testosterone contributes to sexual desire, reproductive function, muscle and bone health, red blood cell production and metabolism. Those roles do not make it a general treatment for tiredness, ageing or sexual performance. Similar symptoms can arise from sleep disturbance, depression, medicines and other health conditions.
Symptoms and the hormonal system
Most testosterone is made by Leydig cells in the testicles, under signals from the hypothalamus and pituitary in the brain. LH and FSH are part of this communication with the testes. A problem can arise within the testicle, from inadequate hormonal stimulation or through functional suppression associated with other illness.
Reduced desire, fewer spontaneous or morning erections and erection difficulty can be compatible symptoms. Some men also report changes in energy, strength, body composition or mood. Physical findings can include changes in muscle, body hair, testicular size or bone health. None of these is a stand-alone home diagnostic test.
Sexual desire, erections, orgasm and sperm production are different functions. Normal testosterone does not exclude vascular or neurological erectile dysfunction, and high desire does not prove a high hormone level. The main erectile dysfunction guide addresses that wider assessment; morning erections are discussed as one clue rather than a hormone test.
The EAU male hypogonadism guideline requires clinical features and biochemical evidence together. A symptom list without appropriate measurements, or a low number without the clinical context, is an incomplete assessment.
Primary, secondary and functional causes
Primary hypogonadism means the testicle cannot produce sufficient testosterone. Possible causes include some genetic conditions, significant injury, previous undescended testes, testicular infection, chemotherapy or radiotherapy and certain operations. LH and FSH patterns can help indicate a testicular-level problem.
Secondary hypogonadism involves inadequate stimulation from the hypothalamus or pituitary. Pituitary disease, raised prolactin, opioids, some medicines, systemic illness and congenital hormonal conditions may be relevant. Low testosterone with low or inappropriately normal LH or FSH may prompt further endocrine assessment. Prolactin testing or pituitary imaging is selected for the findings rather than performed automatically for every low result.
Functional suppression is associated with factors such as obesity, metabolic disease, chronic illness and some medication. Low testosterone does not always mean permanent testicular failure. Addressing an underlying condition, weight and metabolic health can improve the situation in some men. This does not replace treatment for a genetic condition or significant pituitary or testicular disease.
Age can influence testosterone, but there is no obligatory abrupt transition equivalent to female menopause at one fixed age. Being fifty or seventy is not a diagnosis and does not automatically require treatment. General health and accompanying conditions remain relevant. Age alone should not explain every change in desire or erections.
Taking and confirming a testosterone measurement
EAU guidance recommends morning total testosterone, generally between 07:00 and 10:00, in the fasting state using a reliable assay. Levels vary through the day and may be affected by food. Shift work and night work require the sleep pattern to be considered, so tell the clinician before arranging the sample. Appropriate sampling after adequate sleep matters.
Acute illness can temporarily lower the result. A sample during fever or significant illness may not reflect the usual hormonal state. Record the date, time, fasting status, recent sleep and medication when bringing an existing result. A random low value should not lead directly to a prescription.
Low total testosterone needs confirmation on separate appropriately obtained measurements before treatment. The EAU uses 12 nmol/L, approximately 3.5 ng/mL or 346 ng/dL, as a threshold in symptomatic late-onset hypogonadism. The AUA uses a total testosterone below 300 ng/dL as a reasonable diagnostic cutoff with two separate early-morning measurements. These frameworks do not make one number an individual diagnosis without symptoms and valid sampling. Laboratory methods and units also matter.
Total testosterone, free testosterone and further tests
Much of the circulating testosterone is bound to proteins. Sex hormone-binding globulin, or SHBG, can affect interpretation of total testosterone. Obesity, age, thyroid or liver conditions and medicines may alter it. Selected people may need SHBG, albumin and a calculated free testosterone assessment. Not every direct free-testosterone method has the same accuracy, and everyone does not need that test.
The next aim is to understand the cause. LH, FSH, prolactin and other hormonal or metabolic tests may be selected. Blood count and haematocrit, glucose or HbA1c, lipids and thyroid tests may be relevant according to the presentation. A fixed hormone package or brain MRI for every person with one low value is not the guideline approach.
Bring the full laboratory report with units and reference ranges. If a second sample differs, the clinician can compare conditions as well as results. Symptoms and repeated measurements help decide whether the picture fits primary, secondary or functional hypogonadism, or whether another explanation needs attention.
Desire, erections and lifestyle
Low testosterone can contribute to sexual symptoms, but it is not the cause of every erectile difficulty. In confirmed hypogonadism, treatment may improve some sexual symptoms. Giving testosterone to someone with normal levels does not remove vascular, neurological, psychological or anatomical contributors to erectile dysfunction.
Low desire can also reflect depression, stress, relationship difficulties, poor sleep, chronic illness, pain, medication, alcohol or abnormalities involving thyroid hormones or prolactin. An erection medicine does not correct testosterone deficiency, and the response to one does not establish a hormone diagnosis.
Weight management, physical activity, sufficient sleep and treatment of accompanying illness can help some men with functional suppression. They are not a cure for all forms of hypogonadism. Similarly, “testosterone booster” or “natural testosterone” on a supplement label does not establish clinical benefit, product purity or suitability. The unregulated-product guide discusses related uncertainty.
Treatment and the fertility discussion
Treatment may be considered when compatible symptoms coexist with confirmed low levels, the cause has been assessed and there is no major contraindication. Cardiovascular history, prostate status, blood count, sleep-related breathing problems and medication are reviewed. Expectations should be specific to the diagnosed problem, not promises of rejuvenation or enhanced performance.
External testosterone can suppress sperm production. Tell the clinician about plans for children before treatment begins. Testosterone taken from outside the body can suppress LH and FSH signalling, reduce intratesticular testosterone and lower sperm production. In some men, no sperm are seen in the ejaculate. It is not a treatment for male infertility.
EAU advises against testosterone as treatment for infertility and in men seeking fatherhood. A different hormonal approach may be relevant depending on the cause, but that requires specialist assessment. The male infertility guide addresses reproductive evaluation. Do not start testosterone and postpone the fertility conversation until a later semen test.
Cardiovascular and prostate questions
The TRAVERSE randomised trial enrolled 5,246 men aged 45–80 with symptoms, confirmed low testosterone and existing or high cardiovascular risk. Mean follow-up was about 33 months. Testosterone was non-inferior to placebo for major cardiovascular events. Atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent in the testosterone group. The study does not establish unrestricted use or safety for everyone outside that population.
EAU recommends cardiovascular assessment before treatment and closer monitoring with known disease. Physiological replacement has not been shown by strong evidence to increase prostate-cancer risk, while long-term prospective safety remains relevant. Active prostate cancer is a contraindication. A history of treated prostate cancer requires a more detailed, selected specialist discussion rather than a general rule from a webpage.
These questions should be considered before choosing a preparation. No formulation can be assumed suitable solely because a friend used it. Treatment duration also depends on the cause: permanent testicular failure and potentially reversible functional suppression are not managed identically.
Monitoring and preparing for review
Testosterone can raise red blood cell production and sometimes haematocrit excessively. Monitoring includes symptoms, hormone levels and blood count, with prostate or PSA evaluation according to age and risk and review of cardiovascular or metabolic factors. EAU describes testosterone and haematocrit checks at three, six and twelve months and then yearly, with closer follow-up where needed. The clinician adapts the plan to the person.
Urology may be a starting point for sexual symptoms, testicular findings or fertility concerns. Endocrinology may also be needed for pituitary disease, complex hormone patterns or several hormone deficiencies. The aim is to understand the cause rather than simply issue testosterone.
For a low result, you can request an assessment in Antalya. Bring the full report, earlier results with collection times, medication and details of recent illness or disrupted sleep. Say clearly if children are planned. Confirmation, investigation of the cause and observation may be part of the discussion as well as treatment.
Sources5 sources
European Association of Urology · 2026
EAU Sexual and Reproductive Health Guidelines 2026 — Male HypogonadismEAU Patient Information · 2026
Male HypogonadismAmerican Urological Association
Evaluation and Management of Testosterone Deficiency GuidelineTürkiye Endokrinoloji ve Metabolizma Derneği
HipogonadizmLincoff AM, Bhasin S, et al. · New England Journal of Medicine · 2023
Cardiovascular Safety of Testosterone-Replacement TherapyPubMed: 37326322